Valuation : Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.35B 201M 173M 163M 149M 278M 18.98B 279M 1.92B 746M 9.74B 755M 739M 31.38B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 1.13B 168M 145M 136M 124M 232M 15.85B 233M 1.61B 623M 8.13B 631M 617M 26.21B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.32%
Yield 2024 *
-
Yield 2025 -
08-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/10/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08/09/25 Shanghai Rightongene Biotechnology's boards elects chairman RE
28/08/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/04/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25/02/25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
19/02/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
17/02/25 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
02/01/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
29/10/24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
1 day-0.16%
1 week-1.21%
Current month-3.62%
1 month+8.86%
3 months+1.37%
6 months-14.12%
Current year-7.17%
1 week 24.3
Extreme 24.3
25.8
1 month 21.98
Extreme 21.98
25.8
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
33.27
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 21/07/2024
Director of Finance/CFO 34 26/01/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 53 23/08/2023
Chairman 69 21/07/2024
Director/Board Member 41 12/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%-1.21%-14.89%-36.19% 201M
+0.23%-0.06%+168.44%+357.12% 21.66B
-2.24%-1.33%-37.24%-20.96% 10.16B
-0.90%+1.80%+348.78%+19.38% 8.16B
-0.99%-2.18%-28.06% - 7.08B
-0.01%+0.20%+84.42%+52.87% 6.59B
+2.34%-1.27%-20.74%-15.41% 6.03B
-1.82%-1.64%-8.48%-20.67% 4.33B
-0.62%-0.38%+74.99%+85.77% 4.22B
+1.82%-0.27%-18.67%-28.71% 2.81B
Average -0.24%-0.74%+54.85%+43.69% 7.12B
Weighted average by Cap. -0.33%-0.27%+92.27%+126.57%

Financials

2024 2025
Net sales 242M 36.09M 31.06M 29.22M 26.69M 49.93M 3.41B 50.07M 345M 134M 1.75B 136M 133M 5.63B 177M 26.4M 22.72M 21.38M 19.53M 36.53M 2.49B 36.63M 253M 98.02M 1.28B 99.15M 96.98M 4.12B
Net income -15.76M -2.35M -2.02M -1.9M -1.74M -3.25M -222M -3.26M -22.46M -8.72M -114M -8.82M -8.63M -366M -50.38M -7.5M -6.46M -6.08M -5.55M -10.38M -708M -10.41M -71.79M -27.86M -363M -28.18M -27.56M -1.17B
Net Debt -210M -31.32M -26.95M -25.36M -23.17M -43.34M -2.96B -43.46M -300M -116M -1.52B -118M -115M -4.89B -222M -33.14M -28.51M -26.83M -24.51M -45.84M -3.13B -45.97M -317M -123M -1.61B -124M -122M -5.17B
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
336
Date Price Change Volume
04/09/26 CN¥24.46 -0.16% 1,035,211
03/09/26 CN¥24.50 -3.16% 817,870
02/09/26 CN¥25.30 +0.08% 614,322
01/09/26 CN¥25.28 -0.39% 889,487
31/08/26 CN¥25.38 +2.50% 933,042

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688217 Stock